Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

(2022) Silvio Danese et al.   LANCET

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

(2021) Séverine Vermeire et al.   Journal of Crohns & Colitis

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

(2021) Dan Turner et al.   GASTROENTEROLOGY

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

(2021) Brian G Feagan et al.   LANCET

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

(2021) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of sphingosine-1-phosphate in ulcerative colitis

(2020) Marjorie Argollo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis

(2020) Siddharth Singh et al.   GASTROENTEROLOGY

JAK inhibitors safety in ulcerative colitis: practical implications

(2020) Manasi Agrawal et al.   Journal of Crohns & Colitis

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

(2019) Pierre-Eric Juif et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis

(2019) William J. Sandborn et al.   GASTROENTEROLOGY

Sphingosine-1-phosphate receptors and innate immunity

(2018) Arielle M. Bryan et al.   CELLULAR MICROBIOLOGY

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator

(2017) Jonathan Q. Tran et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

(2016) Pierre-Eric Juif et al.   Expert Opinion on Drug Metabolism & Toxicology

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis

(2015) Adnan M. Subei et al.   CNS DRUGS

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fingolimod-associated macular edema: Incidence, detection, and management

(2012) N. Jain et al.   NEUROLOGY

Development of gatekeeping strategies in confirmatory clinical trials

(2011) Alex Dmitrienko et al.   BIOMETRICAL JOURNAL

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation

(2011) T. Hla et al.   NEUROLOGY

Mixtures of multiple testing procedures for gatekeeping applications in clinical trials

(2011) Alex Dmitrienko et al.   STATISTICS IN MEDICINE